Metastatic Prostate Cancer Articles & Analysis
33 news found
These molecules can bind to targets highly expressed on cancer cell surfaces and be targeted during drug delivery. For example, folic acid (folates) can be used. ...
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. The poster was recently presented at the ESMO ...
Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models. ...
ByBayer AG
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering ...
ByBayer AG
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral ...
ByBayer AG
Nubeqa is already approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease. ...
ByBayer AG
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor ...
ByBayer AG
Despite these treatments, a large proportion of men with mHSPC will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), a condition with high morbidity and limited survival. ...
ByBayer AG
The data were presented during poster sessions at the 34th Symposium on Molecular Targets and Cancer Therapeutics hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) in Barcelona, Spain. ...
It is also approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) in a number of markets including the U.S. ...
ByBayer AG
Nubeqa™ (darolutamide), which has the potential to become the standard of care for prostate cancer patients from the early- to the late-stage of this disease, has projected peak sales potential of more than three billion euros. Its market share in the US has already expanded to over 30 percent in non-metastatic castration-resistant ...
ByBayer AG
The biotech firm develops small molecules that target key proteins (called enzymes) in cancer. The company’s first candidate targets the prostate specific membrane antigen (PSMA) in prostate cancer, which is proposed to have both diagnostic and therapeutic applications. Two drugs are being developed, CTT1057 and CTT1403, ...
Despite these treatments, a large proportion of men with mHSPC will eventually progress to metastatic castration-resistant prostate cancer (mCRPC), a condition with high morbidity and limited survival. ...
ByBayer AG
Improvements in the secondary endpoints supported the benefit observed in the primary endpoint, overall survival4. About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. ...
ByBayer AG
Bria-Pros™ is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. Waisman Biomanufacturing has entered an agreement with BriaCell to manufacture clinical supplies for BriaCell’s anticipated clinical trial in advanced prostate cancer. ...
About Metastatic Hormone-Sensitive Prostate Cancer Prostate cancer is the second most commonly diagnosed malignancy in men worldwide. ...
ByBayer AG
OnkosXcel, a Company subsidiary, to utilize proprietary AI-powered platform to progress therapies to address difficult-to-treat cancers with high unmet need New structure to unlock growth opportunities and maximize value of neuroscience and immuno-oncology franchises Lead pipeline asset, BXCL701, has shown clinical proof-of-concept in aggressive forms of ...
Basel, March 23, 2022 — Novartis announced today that the US Food and Drug Administration (FDA) approved PluvictoTM (lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic ...
Raise in peak sales expectations follows presentation of positive Phase III trial ARASENS with darolutamide (Nubeqa) in metastatic hormone-sensitive prostate cancer at 2022 ASCO GU Cancers Symposium and publication in The New England Journal of Medicine on February 17, 2022 Broad development program underway with three ...
ByBayer AG
“Metastatic prostate cancer is a uniformly fatal disease and despite progress in recent years, only 30% of these men will survive beyond five years. ...
ByBayer AG